AR130558A2 - PHARMACEUTICAL COMPOSITION INCLUDING LEDIPASVIR AND SOFOSBUVIR, PHARMACEUTICAL DOSAGE FORM AND TABLET INCLUDING IT - Google Patents
PHARMACEUTICAL COMPOSITION INCLUDING LEDIPASVIR AND SOFOSBUVIR, PHARMACEUTICAL DOSAGE FORM AND TABLET INCLUDING ITInfo
- Publication number
- AR130558A2 AR130558A2 ARP230102532A ARP230102532A AR130558A2 AR 130558 A2 AR130558 A2 AR 130558A2 AR P230102532 A ARP230102532 A AR P230102532A AR P230102532 A ARP230102532 A AR P230102532A AR 130558 A2 AR130558 A2 AR 130558A2
- Authority
- AR
- Argentina
- Prior art keywords
- ledipasvir
- pharmaceutical composition
- sofosbuvir
- dosage form
- pharmaceutical
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Composiciones farmacéuticas con una cantidad eficaz de ledipasvir sustancialmente amorfo y una cantidad eficaz de sofosbuvir sustancialmente cristalino. La composición farmacéutica en donde el Iedipasvir se formula como una dispersión sólida que comprende Iedipasvir disperso dentro de una matriz de polímero formada por un polímero farmacéuticamente aceptable. Reivindicación 2: La composición farmacéutica de la reivindicación 1, caracterizada porque ledipasvir es formulado como una dispersión sólida que comprende ledipasvir disperso dentro de una matriz polimérica formada mediante un polímero farmacéuticamente aceptable.Pharmaceutical compositions with an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir. The pharmaceutical composition wherein Iedipasvir is formulated as a solid dispersion comprising Iedipasvir dispersed within a polymer matrix formed by a pharmaceutically acceptable polymer. Claim 2: The pharmaceutical composition of claim 1, characterized in that ledipasvir is formulated as a solid dispersion comprising ledipasvir dispersed within a polymer matrix formed by a pharmaceutically acceptable polymer.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361759320P | 2013-01-31 | 2013-01-31 | |
| US202061772292P | 2020-03-04 | 2020-03-04 | |
| US202061828899P | 2020-05-30 | 2020-05-30 | |
| US202061870729P | 2020-08-27 | 2020-08-27 | |
| US202061897793P | 2020-10-30 | 2020-10-30 | |
| US202061907332P | 2020-11-21 | 2020-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR130558A2 true AR130558A2 (en) | 2024-12-18 |
Family
ID=93933517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102532A AR130558A2 (en) | 2013-01-31 | 2023-09-22 | PHARMACEUTICAL COMPOSITION INCLUDING LEDIPASVIR AND SOFOSBUVIR, PHARMACEUTICAL DOSAGE FORM AND TABLET INCLUDING IT |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR130558A2 (en) |
-
2023
- 2023-09-22 AR ARP230102532A patent/AR130558A2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR115939A2 (en) | COMPOSITION CONTAINING ULTRA-MICRONIZED PALMITOYL-ETHANOLAMIDE | |
| CL2016000882A1 (en) | Compositions of arni against component c5 of the complement and methods for its use (divisional sol. No. 2710-15). | |
| UY35298A (en) | FORMULATION IN SOLID DISPERSION OF AN ANTIVIRAL COMPOUND | |
| PE20150631A1 (en) | CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR | |
| CL2016000153A1 (en) | Glioxamide substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis b | |
| PE20151778A1 (en) | COMBINED FORMULATION OF TWO ANTIVIRAL COMPOUNDS | |
| MX375001B (en) | DEXMEDETOMIDINE PREMIX FORMULATION. | |
| PE20150092A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE | |
| CU24397B1 (en) | DERIVATIVES OF PIPERIDINIL-INDOL AS INHIBITORS OF THE COMPLEMENT FACTOR B | |
| UY35040A (en) | PIRROLOPIRIMIDINILAMINO-BENZOTIAZOLONAS REPLACED | |
| CO6741223A2 (en) | Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases | |
| PH12015501096A1 (en) | Composition for immediate and extended release | |
| PE20140255A1 (en) | DISPERSIBLE TABLET IN ORAL FORM | |
| CL2015002755A1 (en) | Antibiotic compositions of ceftolozano. | |
| PH12016500793A1 (en) | Turmeric extract containing soft pastilles | |
| CL2015001610A1 (en) | Compounds derived from pyrimido- [4,5-b] -quinoline-4,5 (3h, 10h) -diones to be used as a medicament for the treatment of a disease caused by a nonsense mutation; composition and pharmaceutical combination that includes them. | |
| GT201500035A (en) | ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF MICROSPHERES AND ELABORATION PROCESS | |
| UY35301A (en) | FORMULATION IN SOLID DISPERSION OF AN ANTIVIRAL COMPOUND | |
| MX378946B (en) | BINDER COMPOSITIONS AND METHODS FOR MANUFACTURING AND USING THE SAME. | |
| MX2016008429A (en) | DERIVED FROM PIRANOCROMENIL PHENOL, AND PHARMACEUTICAL COMPOSITION TO TREAT A METABOLIC SYNDROME OR INFLAMMATORY DISEASE. | |
| DOP2016000007A (en) | SUBSTITUTED PIRAZOLPIRIDINS | |
| GT201400003A (en) | A NEW THERAPEUTIC COMPOSITION THAT CONTAINS APOMORPHINE AS AN ACTIVE PRINCIPLE | |
| UY35848A (en) | TIENOPIRIMIDINS | |
| CL2016001094A1 (en) | Microporous zirconium silicate for the treatment of hyperkalemia. | |
| CL2015002817A1 (en) | Formulation of amorphous calcium l-5-methyltetrahydrofolate (l-5-mthf-ca). |